 
Clinical Protocol Number: CTx -1301 -001 
 
A randomized, single -dose, four -sequence, four -period, in -clinic crossover study in adult ADHD subjects 
to establish safety, tolerability, and comparative bioavailability of CTx -1301 (dexmethylphenidate) to the 
listed drug (Focalin XR™) under fasted condit ions. 
 
 
[STUDY_ID_REMOVED]  
 
16Jan2020  
 
 
Protocol CTx-1301 -001                               Version 4.0 , Date:  [ADDRESS_92917] S TO ESTABLISH 
SAFETY , TOLERABILITY,  AND COMPARATIVE BIOAVAILABLITY  OF CTx-
1301 ( DEXMETHYLPHENIDATE ) TO THE LISTED DRUG  
(FOCALIN XR ™) UNDER FASTED CONDITIONS   
Study Number: CTx -1301 -001 
Drug Development Phase:  Phase [ADDRESS_92918]:  Dexmethylphenidate  
Indication:  Attention -Deficit/Hyperactivity Disorder 
(ADHD)  
Sponsor:  Cingulate Therapeutics  
[ADDRESS_92919]  
Kansas City, KS 6620 5 
Principal Investigator  [INVESTIGATOR_85289], MD  
Date:  Version 4.[ADDRESS_92920] :  In accordance with the ethical principles that originate from the Declaration of Helsinki and 
that are consistent with International Conference on Harmonisation (ICH) guidelines on Good Clinical 
Practice (GCP) and regulatory requirements as applicable.  
 
 
 
 
 
Confidential Informat ion 
This document is the sole property of Cingulate Therapeutics. This document and any and all 
information contained herein has to be considered and treated as strictly confidential.  This document 
shall be used only for the purpose of the disclosure here in provided.  No disclosure or publication 
shall be made without the prior written consent of Cingulate Therapeutics.  
 
 
 
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 2 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL   
 
 
 
 
SUMMARY INFORMATION  
 
Title:  A randomized, single -dose, four-sequence, four-period, in-
clinic crossover study in adult ADHD subjects to establish 
safety, tolerability, and comparative bioavailability of CTx -
1301 (dexmethylphenidate) to the listed drug  
(Focalin XR™) under fasted conditions .  
 
 
Protocol Number:   
CTx-1301 -001 
 
 
Sponsor:   
Cingulate Therapeutics  
 
Primary Sponsor contact:  [CONTACT_85310]  
[ADDRESS_92921]  
Kansas City, KS 6620 5 
E: [EMAIL_1712]   
P: [ADDRESS_92922]:  Matt Brams, MD  
Cingulate Therapeutics  
[ADDRESS_92923]  
Kansas City, KS 6620 5 
E: [EMAIL_1713]   
P: 713 -557-8374  
 
Principal Medical Investigator:  Debra Kelsh, MD  
E: [EMAIL_1714]  
P: 913 -696-1601  
 
Study Site:  Altasciences  Clinical Kansas , Inc.  
[ADDRESS_92924] nue 
Overland Park, KS [ZIP_CODE]  
P: 913 -696-1601  
 
Bioanalytical Site:  Altasciences  
575 boul. Armand -Frappi[INVESTIGATOR_85290], Quebec H7V 4B3  
Canada  
P: [PHONE_2002]  
 
 
  
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 3 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL  SPONSOR PROTOCOL APPROVAL  
 
 
Protocol Title:  A randomized, single -dose, four -sequence, four -period, in -
clinic crossover study in adult ADHD subjects to establish 
safety, tolerability, and comparative bioavailability of CTx -1301 
(dexmethylphenidate) to the listed drug  
(Focalin XR™) under fasted condi tions .  
 
 
Protocol Number:   
CTx-1301 -001 
 
Protocol Version:  4.0 
 
Date of Version:  16 January  2020 
Signed for approval by:   
 
 
 
[INVESTIGATOR_124]. Matt Brams , MD 
Chief Medical Officer  
Cingulate Therapeutics    
 
     
 
 
 
 
 
 
 
[CONTACT_85350], MD  
Chief Science Officer  
Cingulate Therapeutics   
 
 
   
  
Protocol CTx-[ADDRESS_92925] read and understand the contents of this clinical protocol for Study No. CTx-
1301 -001 date 16 January 2020  and agree to meet all obligations of Cingulate 
Therapeutics  as detailed in all applicable regulations and guidelines.  
 
Signed By:  
 
[INVESTIGATOR_678]  
[INVESTIGATOR_85291], Inc.    Date of Signature  
 
____________________________________  ________________________________  
 
 
 
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 5 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL  TABLE OF CONTENTS  
 
SUMMARY INFORMATION  ................................ ................................ ................................ ................................ ...... 2 
SPONSOR PROTOCOL APPROVAL ................................ ................................ ................................ ..........................  3 
TABLE OF  CONTENTS  ................................ ................................ ................................ ................................ ...............  5 
TABLES  ................................ ................................ ................................ ................................ ................................ .........  6 
FIGURES  ................................ ................................ ................................ ................................ ................................ ....... 6 
STUDY SYNOPSIS ................................ ................................ ................................ ................................ .......................  7 
ABBREVIATIONS ................................ ................................ ................................ ................................ ........................  9 
INTRODUCTION ................................ ................................ ................................ ................................ ........................  17 
1 OBJECTIVES  ................................ ................................ ................................ ................................ .....................  18 
1.1 PRIMARY OBJECTIVE(S)  ................................ ................................ ................................ .......................  18 
1.2 SECONDARY OBJECTIVE(S)  ................................ ................................ ................................ ................  19 
1.3 EXPLORATORY OBJECTIVE(S) ................................ ................................ ................................ ............  19 
2 ENDPOINTS  ................................ ................................ ................................ ................................ .......................  19 
2.1 PRIMARY ENDPOINT(S)  ................................ ................................ ................................ ........................  19 
2.2 SECONDARY ENDPOINT(S)  ................................ ................................ ................................ ..................  19 
2.3 EXPLORATORY ENDPOINT(S)  ................................ ................................ ................................ .............  [ADDRESS_92926] REPLACEMENT  ................................ ................................ ................................ .....................  24 
4.7 SUBJEC T RESTRICTIONS  ................................ ................................ ................................ ......................  25 
5 STUDY TREATMENTS: ASSIGNMENT & SUPPLY MANAGEMENT  ................................ ......................  [ADDRESS_92927] CONTINUED ELIGIBILITY ASSESSMENT  ................................ ................................ ........  34 
7.3 MEAL SCHEDULE  ................................ ................................ ................................ ................................ ... 34 
7.4 EARLY TERMINATION DAY  ................................ ................................ ................................ ................  34 
7.5 DURA TION OF THE STUDY  ................................ ................................ ................................ ..................  34 
8 PHARMACOKINETICS  ................................ ................................ ................................ ................................ .... 34 
8.1 PHARMACOKINETIC BLOOD SAMPLING  ................................ ................................ .........................  34 
8.2 BIOANALYSIS OF PLASMA SAMPLES  ................................ ................................ ...............................  35 
9 SAFETY MEASUREMENTS AND EVALUATIONS  ................................ ................................ .....................  35 
9.1 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS  ................................ ................................ .. 35 
9.2 PREGNANCY  ................................ ................................ ................................ ................................ ............  39 
9.3 LABORATORY EVALUATIONS RELATED TO SAFETY  ................................ ................................ .. 40 
9.4 VITAL SIGNS AND OTHER OBSERVATIONS RELATED TO SAFETY ................................ ...........  40 
10 STATISTICAL/DATA ANALYSIS METHODS  ................................ ................................ ..........................  40 
10.1 GENERAL CONSIDERATIONS  ................................ ................................ ................................ ..............  40 
10.2 STATISTICAL AND ANALYTICAL PLAN  ................................ ................................ ...........................  41 
10.3 STUDY OBJECTIVES  ................................ ................................ ................................ ..............................  41 
10.4 SAMPLE SIZE DETERMINATION  ................................ ................................ ................................ .........  41 
10.5 ANALYSIS POPULATIONS  ................................ ................................ ................................ ....................  41 
10.6 DEMOGRAPHIC AND BASELINE CHARACTERISTICS  ................................ ................................ ... 41 
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 6 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL  10.7 PHARMACOKINETIC ANALYSIS  ................................ ................................ ................................ .........  42 
10.8 SAFETY ANALYSIS  ................................ ................................ ................................ ................................  42 
11 ETHICAL A ND REGULATORY ASPECTS ................................ ................................ ................................  43 
11.1 LOCAL REGULATIONS/DECLARATION OF HELSINKI  ................................ ................................ ... 43 
11.2 INFORMED CONSENT  ................................ ................................ ................................ ............................  43 
11.3 INDEPENDENT ETHICS COMMITTEE/INSTITUTIONAL REVIEW BOARD  ................................ . [ADDRESS_92928] KEEPI[INVESTIGATOR_1645]  ...............  43 
12.1 INVESTIGATOR’S FILES/RETENTION OF DOCUMENTS  ................................ ................................  43 
12.2 SOURCE DOCUMENTS/DATA  ................................ ................................ ................................ ..............  [ADDRESS_92929] RECORDS  ................................ ....... 45 
16 AUDITS/INSPECTIONS  ................................ ................................ ................................ ...............................  45 
17 REFERENCES  ................................ ................................ ................................ ................................ ...............  46 
 
 
TABLE S  
TABLE 1: STUDY SYNOPSIS ................................ ................................ ................................ ................................ ..... 7 
TABLE 2: STUDY SCHEDULE ................................ ................................ ................................ ................................ . 11 
TABLE 3: SCHEDULE FOR CHECK -IN AND TOLERABILITY (DAY -4 TO DAY -3) ................................ ..... 13 
TABLE 4: SCHEDULE FOR ASSESSMENT DAYS DAY 0, DAY 3, DAY 6, AND DAY 9 DAYS  ....................  15 
TABLE 5: STUDY TREATMENTS  ................................ ................................ ................................ ...........................  20 
TABLE 6:  STUDY DESIGN AND TREATMENT SEQUENCES  ................................ ................................ ............  20 
TABLE 7: TREATMENT -EMERGENT ADVERSE EVENTS OCCURRING DURING DOUBLE -BLIND 
TREATMENT (ADULTS)  ................................ ................................ ................................ ................................ ..........  28 
TABLE 8  ................................ ................................ ................................ ................................ ................................ ...... 38 
 
 
FIGURES  
FIGURE 1: SCHEMATIC FOR PROPOSED TRIMODAL CTX -1301 TABLET  ................................ ....................  18 
 
 
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 7 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL  Table 1: Study Synopsis   
STUDY SYNOPSIS  
 
Title  
A randomized, single -dose, four -sequence, four -period, in -clinic , crossover 
study in adult ADHD subjects to establish safety, tolerability, and comparative 
bioavailability of CTx -1301 (dexmethylphenidate) to the listed drug  
(Focalin XR™) under fasted conditions .  
 
Short Title/Acronym  CTx-1301 Comparative BA Study  
Protocol Number  CTx-1301 -001 
Objective(s)  Primary objectives:  
• To compare the bioavailability of the marketed product Focalin XR ™ 
Extended -Release Capsul es to the CTx -[ADDRESS_92930]  in a 
fasted state  
• To evaluate  dose proportionality of CTx -1301 by [CONTACT_62085] 6.25 
mg dose to the 50 mg dose  
 
Secondary objective s: 
• To characterize the pharmacokinetic s of dexmethylphenidate  
(d-MPH ) blood plasma levels  after dosing   
• To evaluate safety measurements including ECG, vital signs, lab 
assessments, physical exam, and occurrence  of treatment -emergent 
adverse events  (TEAEs)  
Study Design and 
Methodology  A single -center, randomi zed, four-sequence , four -period , in-clinic,  crossover 
study  in a fasted state . 
Subjects will be enrolled in approximately 4-5 cohorts ( each cohort will enroll 
approximately 6-12 subjects/cohort)  to allow for a recruitment total of 
approximately [ADDRESS_92931] s aged 18 to 55 years, inclusive, free from any significant 
diseases /disorders (e.g. psychiatric  (excluding ADHD) , cardiac, hepatic, renal , 
and gastrointestinal ), and can demonstrate tolerability of a single dose of [ADDRESS_92932] , CTx -1301,  is a (Precision Timed Release™ 
(PTR™) trimodal  release d-MPH tablet using an erosion -barrier layer (EBL) 
technology. The investigational doses  of CTx -1301  in this study  are 6.25 mg 
and 50 mg  (d-MPH ). 
 
Tablets will be taken orally with [ADDRESS_92933]  (Listed Drug (RLD)) used in this study  is Focalin  XR™ 
5 mg  and Focalin  XR™  40 mg  (d-MPH) . 
 
Capsules will be taken orally with 240 mL room temperature water.  
 
All capsules  will be administered under fasted conditions . 
Treatments  Four treatments  
a. (1) Focalin XR 5mg  
b. (1) CTx -1301 trimodal  dMPH 6.25mg  
c. (1) Focalin XR 40mg  
d. (1) CTx -[ADDRESS_92934]’s involvemen t in the study will be 15 days  in-clinic  (excluding 
screening) . Completion of the clinical study  will be defined as last subject, last 
visit (LSL V) at End of Study (EOS) visit .  
Treatment Duration  Subjects will check in on Day -4, receive a test dose  for tolerability (40 mg 
Focalin XR)  on Day -3, and if eligible, will be randomized to the study.  The 
study  treatment will be administered according to the randomization schedule 
at Day 0, Day 3, Day 6, and Day 9 ; subjects  will remain in clinic throughout the 
study.  End of study/last visit is  the EOS visit . 
 
Dosing will be separated by  72 hours  (3 days)  to allow washout of study  drug 
and reference drug (d -MPH) .  
PK Sampling Times  Pre-dose  (0) and Hours 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 
16, 20, 24, and 28.  
 
Criteria for Evaluation  
Pharmacokinetics  The pharmacokinetic parameters to be determi ned are:  
Maximum Concentration (C max), Time of Maximum Concentration (T max), 
terminal elimination constant (K), lag time (T lag), Half Life (T 1/2), Area Under the 
Curve from time 0 to 28 hrs (AUC last), Area Under the Curve from time 0 to 
infinity (AUC 0-), and partial areas  AUC 0-3, AUC 3-6, AUC 6-9, and AUC 9-12, and 
AUC 12-16.  Additional measures may be evaluated  if deemed necessary . 
Bioanalytical Method  Analysis of d -MPH in plasma will utilize a validated, high-performance liquid 
chromatography ( HPLC ) method using tandaem mass spectrometry ( MS/MS ) 
detection for the determination of methylphenidate in human plasma.  
Safety  All adverse events  (AEs)  will be listed for each subject and summarized by [CONTACT_85311]  (MedDR A) and summarized 
by [CONTACT_6657]. Any serious adverse events (SAEs) 
will be listed separately.  
Statistical Methods  Statistics will be computed and reported for pharmacokinetic and safety  
parameters obtained.   Statistical Analysis Plan (SAP)  will be completed a priori  
and before unblinding and analysis of PK samples . 
Protocol CTx-1301 -001                               Version 4.0 , Date:  [ADDRESS_92935]  Hematocrit  
HPLC  High-performance liquid chromatography  
Hr.  Hour (s) 
ICH  International Conference on Harmonisation  
IEC Independent Ethics Committee  
IRB Institutional Review Board  
K Terminal elimination constant  
kg Kilograms  
kg/m [ADDRESS_92936] Visit 
m Meter 
MCH  Mean Cell Hemoglobin  
MCV  Mean Cell Volume  
MedDRA  Medical Dictionary For Regulatory Activities  
mg Milligram(s)  
min Minute  
mL Milliliter (s) 
mmHg  Millimeters  Of Mercury  
D-MPH  Dexmethylphenidate   
MPH  Racemic Methylphenidate  (d, l-MPH)  
ms Millisecond  
MS/MS  Tandem mass spetcrometry  
mSv Millisieverts  
NCS  Not Clinically Significant  
NMS  Neuroleptic Malignant Syndrome  
PCP Primary Care Physician  
PK Pharmacokinetic  
RBC  Red Blood Cell 
RLD Reference Listed Drug   
SAE Serious Adverse Event 
SAR Serious Adverse Reaction  
SAP Statistical Analysis Plan  
SOP  Standard Operating Procedure  
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 10 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL  TEAE  Treatment Emergent Adverse Event  
T1/2 Half Life  
Tlag Lag time  
Tmax Time of Maximum Concentration  
U Unit 
USV Unscheduled Visit 
WBC  White Blood Cell 
Protocol CTx-1301 -001                               Version 4.0 , Date:  16 January 2020                           Page 11 of 47 
Cingulate Therapeutics                                                                     CONFIDENTIAL  
 Table 2: Study Schedule  
Procedure  Screening a 
(Day -28 to 
Day -5) Clinic  
Check -In 
(Day -4) Tolerability c 
Test 
(Day -3)  
(Day -2) (Day -1) Assessment 
Days  
(Day 0, 3, 6, 
and 9)   
Non-
Assessment 
Days  
(Day 1, 2, 4, 5, 
7, & 8)   
EOS or 
ETll  
Unscheduled 
(USV) m 
Written Informed Consent  ✓      
   
Demographics  ✓        
Medical History  ✓ ✓       
Current/Concomitant 
Medications  ✓ ✓ ✓   ✓ ✓  
Inclusion & Exclusion 
Criteria  ✓ ✓ ✓   ✓ d   
Wash -Out Call  ✓b        
Physical Examination  ✓ ✓    ✓e ✓  
MINI 7.0.2 version  ✓        
C-SSRS  ✓ ✓ ✓   ✓ ✓  
Electrocardiogram (ECG)  ✓ ✓ ✓f   ✓f ✓f  
Vital Signs  ✓ ✓ ✓g   ✓ g ✓g ✓ g  
Height  ✓      
   
Weight  ✓ ✓     ✓  
Serology  ✓        
Clinical  Safety  Labs:    
      
Biochemistry  ✓ ✓ ✓  
Hematology  ✓ ✓ ✓  
Urinalysis  ✓ ✓ ✓  
Serum HCG  ✓h ✓h     ✓h  
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 12 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL  Table 2: Study Schedule  
Procedure  Screening a 
(Day -28 to 
Day -5) Clinic  
Check -In 
(Day -4) Tolerability c 
Test 
(Day -3)  
(Day -2) (Day -1) Assessment 
Days  
(Day 0, 3, 6, 
and 9)   
Non-
Assessment 
Days  
(Day 1, 2, 4, 5, 
7, & 8)   
EOS or 
ETll  
Unscheduled 
(USV) m 
Urine Screen for Drugs of 
Abuse   ✓ ✓       
Breath  Alcohol  Test ✓ ✓       
AE Assessment  ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ongoing Eligibility       ✓ 
 ✓  
Test Dose of 40mg Focalin 
XR™    ✓ c      
Randomization       ✓ i   
Treatment Administration   
     ✓ j   
PK Blood Sampling       ✓ k ✓ k  
 
 
a: Screening day(s) will take place up to 24 days prior to Day -4 (check -in at clinic) . 
b. Washout call reminder should be completed 120 h rs (5 days)  prior to Day -4.  If subject is screened within the [ADDRESS_92937] occur on Day -3, allowing 3 days prior to Day 0  /Randomization to ensure washout of d-MPH . Dosing must  occur by [CONTACT_3450] 8:[ADDRESS_92938] 
can’t tolerate test dose, subject must be excluded.  
d. Inclusion/Exclusion assessed at  Screening, Day -4, and  Day 0 prior to randomization; Eligibility continually assessed throughout study.   
e. PE to occur mid -study on Day 6  
f:  ECG’s administered on tolerability and Assessment days must be done prior to dosing, hr. 6, and hr. 28 (+/-[ADDRESS_92939] -dose ECGs ). 
g  Vital signs will be taken prior to dosing and at [ADDRESS_92940]-dose  (+/- 10 minutes) at tolerability day (Day -3) and Days 0 -9.   
h. Serum HCG  tests should be assessed in women of child -bearing potential  at Screening, Check -In (Day -4), and  EOS /ET. 
i.  Randomization will occur on Day [ADDRESS_92941] still meets inclusion/exclusion criteria  
j.  Administration of study treatment must be separated by 3 days  (72 hours) . Administration of study treatments will occur on Day 0, Day 3, Day 6, and Day 9  by [CONTACT_3450] 8:30 am .   
k. Blood samples for PK analysis will be taken pre -dose  (0)  -1 to 0  hr.) and post -dose at hrs. 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 20, 24, and 28 ; if for ET visit, collect one last 
pk draw and record time of collection.   
l.  Early Termination (ET) day assessments should follow the EOS assessment schedule.  If all assessments are not completed, note reason for noncompletion.  
m. USV is at the discretion of an Investigator ; USV will have no treatment administration  or PK draws/analysis . All other assessments are at the discretion of the investigator.  
 
 
Protocol CTx-1301 -001                               Version 4.0 , Date:  16 January 2020                           Page 13 of 47 
Cingulate Therapeutics                                                                     CONFIDENTIAL  
  Table 3: Schedule for Check -In and Tolerability (Day -4 to Day -3)  
 
Time Relative to 
Dose (h r.)  Subject Activity  Fluid/Food 
intake  d  
ECG c Vital 
signs e Safety and AE Monitoring  
-12 to -10 (check -in, 
Day -4) Assessment of 
eligibility.  
Urine analysis for 
drugs  and breath 
alcohol test  a 
 
  
Fasting from at 
least 10 hr. 
prior to dosing . 
 
Water ad 
libitum  
 
   
Clinical Safety Labs for 
Inclusion/Exclusion  
-1.00 – 0 (pre -dose)  
 Decaffeinated 
Fluids/Water is 
restricted at 
least 1 hr. prior 
to dosing.  ECG  
should 
be taken 
within 60 -
minute 
window 
prior to 
dosing c 
 ✓  
-.50 - 0 (pre -dose)  
0 Dosing   240 mL water  
w/dose     
Continuous AE monitoring  ↨ 
 
Subject to remain 
seated b 
  
Decaffeinated 
Fluids/Water is 
restricted until 
at least 2 hrs 
after dosing.  
 ✓ 
2 ✓ 
↨  
Fasting from 
dosing to at 
least 4 hrs after 
dosing  
 
Water ad 
libitum .  
  
4  Lunch d 
↨ 
  
Water ad 
libitum  
 
6 Snack d ECG c      
✓ 
↨ Water ad 
libitum      
8  
9  Dinner d 
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 14 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL   Table 3: Schedule for Check -In and Tolerability (Day -4 to Day -3)  
 
Time Relative to 
Dose (h r.)  Subject Activity  Fluid/Food 
intake  d  
ECG c Vital 
signs e Safety and AE Monitoring  
↨  
Decaffeinated 
fluid ad libitum  
  
12  Snack d 
↨ 
  
Decaffeinated 
Water / 
decaffeinated 
fluid ad libitum  
 14 
↨ 
[ADDRESS_92942] d 
↨ 
 28 ECG c ✓ 
 
a  Urine analysis for drugs and breath alcohol  test will be conducted and reviewed prior to subject dosing. Tests may be repeated at 
an Investigator's discretion.  
b  Subject must remain seated upright for at least [ADDRESS_92943] is required to be supi[INVESTIGATOR_2525] a study procedure 
or experiences an AE. Brief periods of standing are okay under supervision (e.g., to use the restroom).  Subjects may be ambulatory 
or seated upright from hours 2 - 4.  Activity beyond hour 4 is not restricted with the exception that it shouldn’t i nclude any activity that 
may increase the subject’s heart rate.  
c  An ECG should be taken approximately within 60 minute s prior to dosing, hr. 6, and hr. 28 (± [ADDRESS_92944] -
dose ECGs)  
d Acceptable water, snack, and lunch/dinner times will be considered ± 30 min of the target time , except for hr 4; hr [ADDRESS_92945] occur at 
hr 4 or +[ADDRESS_92946] -dose (+/- 10 minutes).   
 
 
  
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 15 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL  Table 4: Schedule for Assessment Days Day 0, Day 3, Day 6, and Day 9 Days  
Time Relative 
to Dose ( hr.) Subject 
Activity  Blood Sampling  b Fluid/Food 
intake d ECG  Vital signs e AE 
Monitoring  
-12 to -10 
(pre-dose)  Snack is 
available if 
needed  
 Water ad 
libitum  
  
Continuous 
AE 
monitoring  
(subjects 
will not be 
woken to 
answer 
question if 
sleepi[INVESTIGATOR_007])  -10 
  (pre-dose)    
Fasting from 
at least 10 hr. 
prior to 
dosing . 
 
 Water ad 
libitum  
 
-1.0 to 0   
(pre-dose)  
 Venipuncture or 
Insertion of cannula 
and pre -dose 
sample.  Decaffeinated 
Fluids/Water 
is restricted  at 
least     1 hr. 
prior to 
dosing.   
ECG  should 
be taken 
within 60 -
minute 
window prior 
to dosing c 
 Vital signs 
should be 
taken within 60 -
minute window 
prior to dosing  -.50 to 0 
(pre-dose)  
0 Dosing    240 mL water  
w/dose  
  
↨ 
Subject to 
remain seated a Blood sampling 
times: 0.5, 1, 1.5, 2, 
3, 4, 5, 6, 7, 8, 9, 
10, 11, 12, 13, 14, 
15, 16, [ADDRESS_92947]-
dose.  b  
Decaffeinated 
Fluids/Water 
is restricted 
until at least 2 
hrs after 
dosing.  
 ✓ 
2 ✓ 
↨  
Water ad 
libitum  
 
Fasting from 
dosing to at 
least 4 hrs 
after dosing.  
  
4  
 Lunch d 
↨  Water ad 
libitum  
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 16 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL  Table 4: Schedule for Assessment Days Day 0, Day 3, Day 6, and Day 9 Days  
Time Relative 
to Dose ( hr.) Subject 
Activity  Blood Sampling  b Fluid/Food 
intake d ECG  Vital signs e AE 
Monitoring  
6 Snack d ECG c ✓ 
↨ Water ad 
libitum  
  8  
 
9 
 Dinner d 
↨ Decaffeinated 
fluid ad libitum  
12  
 
 Snack d 
↨ 
 Water / 
decaffeinated 
fluid ad libitum  
 14 
↨ 
16  
 
↨ 
 [ADDRESS_92948] d 
↨ 
 
28b ECG c ✓ 
End of 
Assessment 
Day Depart Site  f     
 
a Subject must remain seated upright for at least [ADDRESS_92949] is required to be supi[INVESTIGATOR_2525] a study procedure 
or experiences an AE. Brief periods of standing are okay under supervision (e.g., to use the restroom). Subjects may be a mbulatory 
or seated upright from hours 2 -4.  Activity beyond hr . 4 is not restricted with the exception that it shouldn’t include any activity that 
may increase the subject’s heart rate.  
b An acceptable pre-dose PK blood sampling time will be considered -1 to 0 hr of target time (0). Post -dose PK blood sampling time 
will be consider ed ± 5 min of the target time ; Exact time of PK draw must be re corded to the hr. and minute.  
c  An ECG should be taken approximately within 60 minute s prior to dosing, hr. 6, and hr. 28 (± [ADDRESS_92950] -
dose ECGs)  
d Acceptable water, snack, and lunch/dinner times will be considered ± 30 min of the target time , except for hr 4; hr [ADDRESS_92951] occur at 
hr 4 or +[ADDRESS_92952] -dose (+/- 10 minutes) 
Days [ADDRESS_92953] departs site after hr. 28 on EOS/ ET day.  
 
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 17 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL  INTRODUCTION  
 
Attention -deficit and hyperactivity disorder (ADHD) is the most prevalent psychiatric condition in children. It 
affects approximately 5 -10% of school -aged childre n.1,2,[ADDRESS_92954] on disruptive behavior  was discovered in 1937, when these drugs proved to increase 
compliance, improve academic performance, and reduce m otor activity in hyperactive children .5 
Methylphenidate (MPH) is the most frequently prescribed among stimulant agents. It has proven efficacy 
on ADHD  symptoms .6,7 
 
Prior to the introduction of the enantiopure d -MPH (d -threo -(R,R) -MPH, dexmethylphenidate,) in 2002, all 
clinically used MPH formulations contained a racemic (1:1) mixture of d -threo -(R,R) -MPH and l -threo -(R,R) -
MPH isomers . The development of d -MPH product was based on the findings that similar improvement on 
sustained attention was achieved after treatment with d -equivalent doses of d -MPH and d ,l-MPH, but not 
after l -MPH. 8 Clinical efficacy was highly correlated with plasma concentrations of d -MPH. The elimination 
of the l -isomer does not diminish the efficacy of an acute dose of methylph enidate .9  The efficacy of the d -
isomer was equivalent to the racemic preparation in ameliorating the target symptoms of ADHD and 
increasing academic productivity. Thus, it was thought that the efficacy of MPH resides in the d -
isomer .8,10,11,12  The short acting form of d -MPH  was released to the market 13 and demonstrated clinical 
efficacy lasting slightly over 5 hrs in open label studies .14  
 
To alleviate the need for a mid -day dose (thereby [CONTACT_85312]), a long -acting formulation of d -MPH was developed that could be administered once a day .[ADDRESS_92955] s 
to establish safety and comparative bioavailability of CTx-1301  to the listed drug , Focalin TM XR Extended -
Release Capsules .  
 
As shown in Figure 1 , the release times of the  CTx-1301 trimodal  tablet is expected to be : 
 
1) 1st dose, immediate release (35% of the total daily dose)  
2) 2nd dose, delayed, sustained  release 90 minutes after a 3-4 hour delay  (45% of the total daily 
dose)  
3) 3rd dose, delayed, immediate release 7-[ADDRESS_92956] -dose  (20% of the total daily dose)  
 
 
 
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 18 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL   
 
 
 
 
 
 
 
Figure 1: Schematic for Proposed Trimodal  CTx-[ADDRESS_92957] dose, and meets all inclusion/exclusion criteria, they will 
be considered eligible for randomization into the study.  All subjects will be rand omized to receive four 
treatments throughout the course of the study; one CTx-1301  trimodal  d-MPH  tablet containing 6.25 mg d -
MPH, one Focalin  5 mg  XR capsule , one CTx-1301 50 mg tablet, and one 40 mg Focalin XR capsule . 
Administration of study drug will occur only on Assessment Days; no study drug will b e administered during 
screening  or unscheduled days (USV s).    
 
The lowest  and highest dose s of CTx-1301  (dexmethylphenidate , 6.25 and 50 mg)  were  selected to bridge 
to the lowest and highest doses of Focalin XR  (dexmethylphenidate , 5 and 40 mg) in this comparative BA 
study .  
 
 
 
1 OBJECTIVES  
 
1.1 PRIMARY OBJECTIVE (S) 
 
• To compare the bioavailability of the marketed product Focalin TM XR Extended -Release Capsul es 
to the CTx -[ADDRESS_92958] x-1301 (50 
mg) to Focalin XR (40 mg) dose  
o Demonstrate similar and comparative bioavailability of the lowest dose of CT x-1301 (6.25 
mg) to the lowest dose of Focalin XR (5 mg)  
o Demonstrate dose proportionality of CTx -1301 by [CONTACT_62085] 6.25 mg dose to the 50 
mg dose  
 
 
 
Immediate Release (d -MPH)  
Delayed, Sustained Release (d -MPH)  
Delayed, Immediate Release (d-MPH)  
OralogiK™  
Erosion Barriers  FIGURE 1  
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 19 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL  1.2 SECONDARY OBJECTIVE (S) 
 
• To provide pharmacokinetic data on blood plasma levels of d-MPH  
• To evaluate the safety of CTx-1301 6.25 mg and 50 mg dose  
 
1.3 EXPLORATORY OBJECTIVE(S)  
 
• To further explore the impact of comparative bioavailability of the marketed product Focalin TM XR 
Extended -Release Capsules to the CTx -[ADDRESS_92959] in a fasted state  within selected time 
intervals  
 
2 ENDPOINTS  
 
2.1 PRIMARY ENDPOINT (S) 
 
•  PK parameters including Cmax, AUC 0-inf, and AUC last.  
 
2.2 SECONDARY ENDPOINT (S) 
 
• PK plasma concentrations of d-MPH and PK parameters including  partial AUCs (e.g. AUC 0-3, AUC 3-
6, AUC 6-9, AUC 9-12, and AUC 12-16) to examine potential differences between treatments (CTx -1301 
6.25 mg vs. FocalinTM XR 5 mg and CTx -1301 50 mg vs. Focalin TM XR 40 mg) within selected 
time intervals.  
• PK plasma concentrations of d-MPH and PK parameters including K, T 1/2, tmax, and t lag. 
• Safety measurements including ECG, vital signs, lab assessments, physical exam, and the 
incidence of treatment -emergent adverse ev ents (TEAEs)  
 
2.3 EXPLORATORY ENDPOINT(S)  
 
• Additional exploratory analyses may be conducted to examine potential differences between 
treatments (CTx -1301 6.25 mg vs. Focalin TM XR 5 mg and CTx -1301 50 mg vs. Focalin TM XR 40 
mg) within selected time intervals.  
 
3 INVESTIGATIONAL PLAN  
 
3.1 STUDY DESIGN  
 
This is a randomi zed, single -dose, four-sequence , four-period , in-clinic  crossover  study  under fasted 
conditions . The study  will involve  approximately 36 adult ADHD subjects, male or female .  The Screening 
period will occur from Day -28 to Day -5; subjects  that meet eligibility at screening  must washout of all 
stimulant medications at least [ADDRESS_92960] s will be in -clinic for  the entire duration of the  15-day study  (Day -4 to EOS ).  Study visits 
include: check -in day (Day -4), tolerability assessment  (Day -3), Assessment 1 (Day 0), Assessment 2 (Day 
3), Assessment 3 (Day 6), Assessment 4 (Day 9) , and EOS .  Subjects that early terminate should follow 
the assessment structure of the EOS  day; a final PK draw should be collected and labeled at ET time . 
Additional unscheduled days or assessments may be requested by [CONTACT_85313] .  
 
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 20 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL  Subjects will be dosed with the follow ing treatments according to a pre -defined , balanced , randomiz ed 
crossover  schedule : 
 
Table 5: Study Treatment s 
 
Treatment A  Focalin TM XR Extended -Release capsule 5 mg  
Treatment B  CTx-1301  trimodal 6.25 mg tablet  
Treatment C  Focalin TM XR Extended -Release capsule 40 mg   
Treatment D CTx-1301 trimodal 50 mg tablet  
 
Subjects will be randomized to sequences of treatment according to a 4 x4 Williams design. Williams Design 
is a special case of Latin square design and is balanced for carryover effects.  
 
Table 6: Study Design and Treatment Sequences  
Sequence  Period 1  Period 2  Period 3  Period 4  
1 (n = 9)  A D B C 
2 (n = 9)  B A C D 
3 (n = 9)  C B D A 
4 (n = 9)  D C A B 
 
Subject s must washout  of all stimulant medications  for a minimum of  [ADDRESS_92961] arrive at the clinic on Day -4 for check in (at least 12 hours prior to hr. 0 on Day -3).  S ubjects 
may receive a snack (if needed)  from hours -12 to -10 on Day -4; at -[ADDRESS_92962] day and  
all Assessment Days  (water is restricted at least [ADDRESS_92963] 2 hrs after dosing ).  Blood 
samples for pharmacokinetic analysis will be taken a t the protocol -specified time points until [ADDRESS_92964]-
dose  (see Table 4 ). Vital signs (blood pressure and pulse) and ECG will be taken at the protocol -specified 
time points until  [ADDRESS_92965] completed  all study assessments. The 
maximum period the subjects will be at the study center  is approximately 15 days . 
 
3.2 RATIONALE FOR STUDY DESIGN  
 
This study will use pharmacokinetic  (pk) analysis to investigate the in vivo behavior  of CTx-1301  tablets  
compared to Focalin XR™  (RLD) for bridging to the RLD.  
 
The randomized crossover study  design allows subjects to act as their own control, thereby [CONTACT_85314].  
 
The three -day period  (72 hrs) between Assessment Days is sufficient for the washout of the drug (the 
plasma elimination half -life of d-MPH  is approximately 3 hrs.). Subjects are kept in -clinic  to increase 
compliance  and reduce drop -out rates .  
 
ADHD subjects meeting all inclusion criteria and no exclusion criteria  will be recruited  for the study .  
 
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 21 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL   
4 STUDY POPULATION  
 
4.1 SOURCE AND NUMBER OF SUBJECTS  
 
The study site will recruit potential subjects from its database , referral network,  as well as  local advertising , 
if required.   
 
Approximately 36 subjects will be randomized  in the study  to achieve completion of approximately 32 
evaluable subjects for the full study (approximately 8 in each sequence ).  
 
 
4.[ADDRESS_92966] s for study enrol lment will be based on the results of a screening medical history, 
physical examination,  mental state examination,  vital signs  (blood pressure and pulse) , breath alcohol, 
urine drugs of abuse , tolerance of [ADDRESS_92967] day , and clinical laboratory tests.  All 
screening tests will be performed and assessed by [CONTACT_9260] . The nature of any conditions 
present at the time of the physical  and mental state  examination s and any pre -existing conditions will be 
document ed and carefully evaluated by [CONTACT_39595] . 
 
4.3 INCLUSION CRITERIA  
 
1. Gender  
a. Male or Female  
 
2. Age 
a. Aged between 18 and 55 years inclusive.  
 
3. Weight and BMI  
a. Body weight ≥  50 kg  
b. BMI ≥ 18 and ≤  [ADDRESS_92968] use the double -barrier method (condom and spermicide) 
for birth control during the study and for [ADDRESS_92969] use  an acceptable method of 
contraception , including abstinence from heterosexual intercourse, hormonal contraceptives, 
intrauterine device  (IUD)  with or without hormones, or double -barrier method (e.g. condom and 
spermicide) , during the study and for [ADDRESS_92970] administration of study drug.  
 
5. Consent  
a. Demonstrates understanding of the study and willingness to participate as evidenced by 
[CONTACT_85315] (signed and dated) obtained befor e any study -related 
activities  are performed . 
 
6. Indication  
a. Subject must report history of diagnosis of ADHD . 
 
Protocol CTx-[ADDRESS_92971] be willing and able to safe ly abstain 
from any other ADHD treatment during 96 hrs. prior to check -in on Day -4 and through the 
complete duration of the study.  
 
7. General Health  
a. Good general health (in the opi[INVESTIGATOR_85292] ) with no clinically significant or relevant 
abnormalities o n medical hi story o r physical examination  which could affect the safety of the 
subject or study data . 
b. No vomiting o r fever within [ADDRESS_92972] has sufficient venous access to allow cannulation and /or venipuncture  to obtain the 
required volume of blood for this study.  
 
d. Subject must currently be taking or previously have taken  a stimulant medication for ADHD.  
 
8. Smoking/Caffeine /Alcohol  
a. Subject must be able to refrain from smoking cigarettes [ADDRESS_92973] ’s medication history suggests they will be able to tolerate a [ADDRESS_92974] demonstrate  tolerability  of dexmethylphenidate assessed by [CONTACT_85316]/test 
dose of 40 mg Focalin XR  as evaluated by [CONTACT_093] .  
 
4.4 EXCLUSION CRITERIA  
 
1. Medical History  
 
a. Current and/or recurrent disease  or illness  that, in the opi[INVESTIGATOR_85292] , could affect 
the study conduct , study outcome,  subject safety, or pharmacokinetic  (PK) assessments (e.g. , 
hepatic disorders, renal insufficiency,  non-self-limiting gastrointestinal disorders,  congestive 
heart failure ). 
 
b. Current and/or previous history of any other serious, severe or unstable psychiatric illness  
which in the opi[INVESTIGATOR_871],  may require  treatment  (e.g. anxiety, psychosis, mood 
disorder, motor tics or suicidality)  or make the subject unlikely to fully complete the stud y, 
and/or any condition that presents undue risk from the study medication or procedures.  
 
c. Subject cannot have suicidal thoughts within the last 6 months as supported by [CONTACT_85317] (C -SSRS).  
 
d. Positive test results for Human Immunodeficiency Virus (HIV) -1/HIV -2 antibodies, Hepatitis B 
surface antigen (HBsAg) or Hepatitis C virus antibody (HCVAb) . 
 
e. A family history of sudden cardiac or unexplained death.  
 
f. Any condition or abnormal laboratory finding that could result in h arm to the subject , affect the 
outcome of the study, or suggest unstable medical illness.  
 
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 23 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL  g. As a result of the MINI, medical history , physical examination , and/or screening investigations  
(including ECG res ults, vital signs and/or laboratory abnormality) , an Investigator  considers the 
subject  disqualified  for the study.  
 
h. Subject plans to undergo elective procedures/surgery at any time during the study.  
 
i. Subject has had surgery within the past [ADDRESS_92975] has taken any medication that , in the opi[INVESTIGATOR_85293] , has been shown to alter 
the PK of d-MPH.  
 
b. Use of any prescription medication within 14 days prior to Day -4 (ADHD medications must be 
discontinued at least 96 hours prior to check -in at Day -4), and/or use of any OTC medications 
(such as antacids, vitamins, minerals, dietary/herbal preparations, and nutritional supplements) 
within [ADDRESS_92976] 30 days prior to Day -4, through the duration 
of the study , and for 30 days after the study ends .  
ii. Acetaminophen (up to 2 grams per day) may be used  during the study  under the direction 
of the Investigator .  
iii. On a case -by-case basis, an Investigator is permitted to allow the use of certain 
concomitant medications, for example, to treat an AE, as long as an Investigator 
determines that the medication will not affect the  subject’s safety or study integrity (eg, 
topi[INVESTIGATOR_5910]).  
 
 
3. Alcohol/Substance Abuse  
 
a. Recent history (within the last year) of alcohol or other substance abuse.  
 
b. Subject has positive breath alcohol test or urine test for drugs of abuse  at screening  or check -in 
(except THC). P rescribed ADHD medication  is acceptable during screening but must be stopped  
at least 96 hrs prior to check in at Day -4. Note: At the discretion of an Investigator , the test s may 
be repeated.   If THC is positive at screening or check -in, a cannabis intoxication evaluation will be 
done by [CONTACT_85318] -in on Day -4;  inclusion will be at t he investigator’s discretion,  due 
to the slow release of THC from adipose tissue.  
 
4. Smoking  
 
a. Subject  regularly  smokes more than 10 cigarettes /day (or other nicotine -containing products)  
or Subject has recently discontinued smoking (within the last 3 months )  
 
 
5. Allergy/Intolerance  
 
a. Subject has a history of allergy to  d-MPH , to any component of the  dosage form , or any other 
allergy, which, in the opi[INVESTIGATOR_85293] , contraindicates their participation.  
Protocol CTx-[ADDRESS_92977] study (inclusive of final post -study examination) or 
receipt of an investigational drug within the [ADDRESS_92978] has donated blood , plasma,  or experienced significant blood loss (excess of 500 ml) within 
[ADDRESS_92979] the right to withdraw from the study at any time for any reason. An Investigator also has the 
right to withdraw subjects from the study in the event of intercurrent illness, adverse events (AEs) , or 
treatment failure after a prescribed proced ure, protocol deviations, administrative reasons , or other 
reasons. It is understood by [CONTACT_85319]; therefore, unnecessary withdrawal of subjects should be avoided.  
 
Should  a subject decide to withdraw, all efforts should be made to complete and report the observations as 
thoroughly as possible. Regardless of the reason for withdrawal, a complete final evaluation should be 
made at the time of withdrawal  following the procedu res of EOS , including a final PK draw and an 
explanation of why the subject is withdrawing from the study.  All reasons for early withdrawal must be 
recorded.  
 
If the reason for removal of a subject from the study is an AE or an abnormal laboratory test res ult, the 
principal specific event or test should also be recorded on the source and electronic case report form 
(eCRF)  and AE should be the documented reason for removal . Any AEs ongoing at the final day will be 
followed up until resolved, the condition stabilizes , is otherwise explained, or the subject is lost to follow -
up.   
 
4.[ADDRESS_92980] cohort, enrollment may be evaluated for completeness (e.g. 32 evaluable , 8 per 
sequence,  for planned comparisions) by [CONTACT_85320].  If the requir ed number of evaluable subjects is not achieved, the study may proceed with 
additional cohort recruitment.   
Protocol CTx-[ADDRESS_92981] RESTRICTIONS  
 
4.7.1  Lifestyle  
 
• Subjects must be able to fast for at least [ADDRESS_92982] (Day -3) and for each  Assessment Day (Day 0, 3, 6, and 9) .  
 
• Subjects must not consume any fluids for at least  [ADDRESS_92983] 2 hrs following  
dosing , excluding the 240 mL of water a dministered with the dose.  
 
• Subjects must be able to refrain from smoking [ADDRESS_92984] not smoke more than 1 cigaratte per hour, not to exceed 10 cigarettes  per day. 
 
• Subjects must abstain from alcohol consumption for 48 hrs prior to  check in at Day -4 and for the 
duration of the study.  
 
• Subjects must not consume any caffeine or xanthine -containing beverages or foods ( e.g., tea, coffee, 
chocolate, cola) for  at least  10 hrs prior to Day -4 and for the duration of the study .   
 
• Subject has donated blood, plasma, or experienced significant blood loss (excess of 500 ml) within 3 
months of screening and for the duration of the study.  
 
 
4.7.2  Medications and treatments  
 
• Subjects must discontinue all ADHD medications at least 96 hrs prior to check in at Day -4. 
• Subjects must not use  prescription medication within 14 days prior to Day -4 (ADHD medications 
must be discontinued at least 96 hours prior to Day -4) and/or  use any OTC medications (such as 
antacids, vitamins, minerals, dietary/herbal preparations, and nutritional supplements) within 
[ADDRESS_92985]’s withdrawal from the study.  All deviations should be 
documented in the source  document  and eCRF.  
 
 
5 STUDY TREATMENTS : ASSIGNMENT & SUPPLY  MANAGEMENT  
 
5.1 STUDY TREATMENTS  
 
5.1.1  Identity of study treatm ents  
 
An unblinded clinical staff  member  will dispense the following  treatments according to a pre -defined 
randomization  schedule  provided by [CONTACT_1034]. All treatments will be dispensed in a blinded , closed -lid 
cup to blind the subjects and the study staff . The treatments administered during the study are as follows:  
 
Treatment A  Focalin TM XR Extended -Release capsule [ADDRESS_92986] will receive (1) dose of all four treatment arms  according to the sequence they are randomized 
to (see Table 6 ). All sequences include 1 dose of: Focalin XR [ADDRESS_92987] of a blind ed dosing cup. Subjects will be dosed  sitting down  
and instructed to swallow the dose with 240 ml of  room -temperature water ; all [ADDRESS_92988] swallow the study drug whole, as provided.  After dosing, subjects will remain 
seated upright (no reclining) for at least 2 hours (hrs 0 -2) and seated upright and/or ambulatory for hrs [ADDRESS_92989] and Assessment Day  treatments , will be dosed in the morning  
(by [CONTACT_3450]  8:30 am) ; all subjects must be dose d within approximately [ADDRESS_92990] 2 hrs after dosing; the 
240 mL of room -temperature water with dosing is allowed and required per protocol.  
 
Subjects will be dosed as per the s chedule described in Table 2  in a randomized sequence . 
 
There will be  a 72-hour washout ( 3 days) between each dosing /Assessment  day. 
 
Protocol CTx-[ADDRESS_92991](s) Dispensing 
and Accountability Record  and the source documents; a ny comments on the performance of this procedure 
should be recorded on the source document and e CRF.  
 
Any violation of compliance will require evaluation by [CONTACT_85321].  
 
5.1.7  Precautions  
 
No special precautions are necessary provided that the study is conducted according to this protocol. The 
Principal Investigator [INVESTIGATOR_85294] -being of the subjects during the course of 
the study. Ongoing monitoring days will be conducted by [CONTACT_456] -appointed CRO to ensure compliance 
to the protocol.  
 
5.1.8  Over -dosage  
 
An overdose is a deliberate or inadvertent administration of a treatment at a d ose higher than specified in 
the protocol.   
 
Overdose per se  is not an AE ; it should be recorded as a protocol deviation and the CRO/Sponsor should 
be notified immediately . However, any clinical sequelae of an overdose should be reported as an AE (and 
an SAE, if appropriate). See Section 9.1.2 for reporting instructions.  
 
It is unlikely that over -dosage will occur in this study  as treatments are prepared on an individual basis 
according to an approved manufacturing protocol and administered by [CONTACT_45914], not by [CONTACT_85322] . 
 
5.1.9  Rescue therapy  
 
No rescue therapy is applicable for this study.  
 
5.1.10  Risks  
 
The perceived risks involved in this study relate to:  
 
Drug  
 
The study population may not benefit from the single -dose treatment  at each day. Inclusion and exclusion 
criteria have been chosen in order to enable a uniform study population and to minimize possible risks in 
relation to the administration of CTx-[ADDRESS_92992] common adverse reactions  after taking Focalin TM XR Extended Release capsules  (at least 5% 
and twice the incidence among placebo -treated subject s) are dry mouth, dyspepsia, headache, and anxiety 
for adult subject s. Adverse reactions are expected to be similar for both CTx -1301 and Focalin™ XR based 
on a pi[INVESTIGATOR_85295] -1301.  
 
Table 7  shows the treatment -emergent adverse events resulting from a placebo -controlled, parallel -group 
study in adults with ADHD at fixed Focalin XR doses of 20, 30 and 40 mg per day.  Only events that occurred 
in 5% or more of th e subject s and for which the incidences appear to increase with dose are reported.  
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 28 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL   
Table 7: Treatment -Emergent Adverse Events Occurring during Double -Blind Treatment (Adults)  
 
 Focalin XR  
20 mg  
N=57  Focalin XR  
30 mg  
N=54  Focalin XR  
40 mg  
N=54  Placebo  
 
N=[ADDRESS_92993] s with AEs  
       Total   
84%  
94%  
85%  
68% 
Primary system Organ Class 
/ Adverse Event Preferred 
Term   
Gastrointestinal Disorders  28% 32% 44% 19% 
       Dry Mouth  7% 20% 20% 4% 
       Dyspepsia  5% 9% 9% 2% 
Nervous System Disorders  37% 39% 50% 28% 
       Headache  26% 30% 39% 19% 
Psychiatric Disorders  40% 43% 46% 30% 
       Anxiety  5% 11% 11% 2% 
Respi[INVESTIGATOR_696], Thoracic and 
Mediastinal Disorders  16% 9% 15% 8% 
       Pharyngolaryngeal  Pain 4% 4% 7% 2% 
 
Two other adverse reactions occurring in clinical studi es with Focalin XR at a frequency greater than 
placebo, but which were not dose related were: feeling jittery (12% and 2%, respectively) and dizziness 
(6% and 2%, respectively).  
 
Nervousness and insomnia are the most common adverse reactions reported with ot her Methylphenidate 
HCl Dosage Forms. The following adverse reactions may also occur:  
 
Cardiac: angina, arrhythmia, palpi[INVESTIGATOR_814], pulse increased or decreased, tachycardia  
 
Gastrointestinal: abdominal pain, nausea  
 
Immune: hypersensitivity reactions including skin rash, urticaria, fever, arthralgia, exfoliative dermatitis, 
erythema multiforme with histopathological findings of necrotizing vasculitis, and thrombocytopenic purpura  
 
Metabolism/Nutrition: anorexia, weight loss during prolonged therapy  
 
Nervous System: dizziness, drowsiness, dyskinesia, headache, rare reports of Tourette’s syndrome, toxic 
psychosis  
 
Vascular: blood pressure increased or decreased, cerebral arteritis and/or occlusion  
 
Although a definite causal relationship has not been established, the following have been reported in 
subject s taking methylphenidate:  
 
Blood/Lymphatic: leukopenia and/or anemia  
 
Hepatobiliary: abnormal liver function, ranging from transaminase elevation to hepatic coma  
 
Psychiatric: transient depressed mood, aggressive behavior, libido changes  
 
Skin/Subcutaneous: scalp hair loss  
 
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 29 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL  Urogenital: priapi[INVESTIGATOR_85296] (NMS) have been received, and, in most of these, 
subject s were concurrently receiving therapi[INVESTIGATOR_85297].  
 
Further information can be found in the Focalin TM XR Extended -Release Package Insert . 
 
Blood Sampling  
 
Blood samples will be taken for safety and/or pharmacokinetic assessments during screening and follow -
up medical examinations as  well as on Assessment Days. There is a risk of bruising and fainting during 
blood sampling.    
 
Direct venipuncture or cannula (small plastic tube) may be used to obtain PK samples.  This may be a little 
uncomfortable and may leave a bruise. A cannula may be used because it allows several blood samples  
to be drawn  without the need to insert a needle in t he subject's arm each time. The  cannula may remain in 
place for the duration of the Assessment Day but may need to be re -sited during this time. There is a very 
small risk of inflammation of the vein and  changes in the sensation in the subject's arm following blood 
sampling.  
 
If blood sampling via venipuncture  is not possible , and/or not preferred, a cannula will be inserted  by [CONTACT_38992].  Use of venipunctures and/or cannulas should be recorded in the CRFs.    
 
5.2 STUDY SCREENING PROCEDURE AND TREATMENT ASSIGNMENT  
 
5.2.1  Screening  procedure  
 
A unique screening number will identify all subjects screened for study participation. Screening numbers 
will be noted with an “S” followed by [CONTACT_62360], assigned in ascending numerical  and sequential order , 
according to appearance at the study site , e.g. S -001, S -002, etc . All subjects that consent must be 
assigned a screening number.  A subject who screen fails prior to , or on Day -[ADDRESS_92994] be maintained by [CONTACT_85323] t he source documents and eCRF . 
 
5.2.2  Randomization  procedure  
 
This is a randomized study.  Subjects should only be enrolled and randomized if they meet 
inclusion/exclusion both at screening and again at Day -4, Day -3, and Day -1.   
 
Subjects who meet all of the inclusion and none of the exclusion criteria will be enrolled /randomized  to the 
study. The subject enrollment/randomization numbers correspond to a pre -defined randomization schedule 
prepared by [CONTACT_1034].   Subject enrollment numbers will be assigned in ascending numerical order per 
cohort as enrolled.  Randomization numbers will be assigned in sequence across  cohorts; replacement 
randomization numbers will be formatted in a manner similar to those initially assigned, but uniqu e to the 
replacement patient.   
 
There should be no sequence gaps in subject enrollment  and initial randomization numbers .  If a  subject 
early terminates  that enrollment/randomization number must still remain attached to the early termination 
subject.  If an initial  randomization sequence is skipped, the unblinded pharmacis t (or unblinded qualified 
pharmacy staff)  must immediately consult with the unblinded statistician at the CRO for next steps.  
 
Following the completion of the planned cohorts and replacement assignments, an unblinded statistician 
may review the allocations as described in Section 4.6.  
Protocol CTx-[ADDRESS_92995]  according to the randomization  schedule  provide d by [CONTACT_85324]/CRO .  A second verification by [CONTACT_85325] s are randomized  to the correct randomization sequence per the subject 
enrollment /randomization  number  and ensure that the correct treatment was provided on each treatment 
day. The pharmac y staff  must follow the Site’s pharmacy dispensing SOP. All doses will be administered 
from a blinded cup with a closed lid to prevent subjects from inspecting the tablets or capsules  as well as 
to keep the subjects and study staff blinded.  
 
Note: The tolerability dose on Day -[ADDRESS_92996], white plastic bottles , and will  be labeled as 
specified with the following information: study number, investigational drug name, batch number,  count, 
storage requirements, manufacturing information, and "Caution:  New Drug --Limited  by [CONTACT_4496] (or United 
States) L aw to  Investigational  Use." 
  
Focalin TM XR Extended Release  Capsules are a  commercially  marketed product and will be provided by  
[CONTACT_85326] I unit.  The clinical site will place a label on the bottle stating: Protocol Number 
CTx-[ADDRESS_92997] should be kept up to date 
with the following information:  
 
• The identification of the subject to whom the study treatment was dispensed.  
• The time, date, and assigned treatment  and sequence  of the study treatment dispensed to the 
subject.  
 
In order to comply with FD A rules and regulations, the clinical research unit will retain an adequate 
quantity of reserve samples for the test and reference formulations that shall permit, if required, to 
perform [ADDRESS_92998] emental application (New Drug 
Application [NDA's] or Abbreviated New Drug Application [ANDA's]).  The labeling, storage conditions and 
retention period of the reserve samples shall comply with  the current version of FDA regulation 21 Code 
of Federal Regulat ions (CFR) section 320.38  and/or 320.[ADDRESS_92999] be held at USP controlled -room temperature of 20-25°C.   
 
Throughout the duration of the study, all study medication will be securely stored within the pharmacy .  The 
pharmacy is monitored by [CONTACT_85327], which provides continuous temperature monitoring  and alerts 
the pharmacy staff prior to a temperature deviation.   
 
If a temperature or storage deviation occurs, the CRO and Sponsor should be alerted immediately.   Sponsor 
will determine if excursion falls within acceptable stability limits or if drug should be quarantined.   
 
6 STUDY SCHEDULE  
   
The summary of the  Study Schedule (Table 2 ) includ es a detailed schedule  for the tolerability test day 
(Table 3)  and assessment days (Table 4 ). 
 
[ADDRESS_93000] obtain written (signed and dated by [CONTACT_423]) 
informed consent from each subject, participating in this study after adequate explanation of the aims, 
methods, objectives, and potential hazards of the s tudy.   
 
An Investigator, or medically qualified designee, must also explain to the subjects that they are completely 
free to refuse to enter the study or to  withdraw from it at any time. Appropriate forms for documenting a 
written consent will be provided  by [CONTACT_85328] . An Investigator, or designee, should 
sign and date the consent form to confirm that the consent process was completed correctly.   
 
The subject will be provided with a copy of their signed and dated consent form, along wi th any other written 
information, which they should be instructed to retain.  The original  informed consent must  be stored in the 
regulatory file for the study . All subjects that complete an ICF must have a n assigned screening number.  
 
If, during a subject’ s participation in the study , any new information becomes available that may affect a 
subject’s willingness to participate in the study, each ongoing subject should receive a copy of this new 
information and be re -consented into the study.  Subjects should be provided with a copy of the signed and 
dated amended consent form.    Any new consen t forms must be stored in the regulatory file along with all 
previous signed consent forms.  
 
7.1.[ADDRESS_93001]'s date of birth, gende r, and race  in the source 
documents and eCRF . 
 
7.1.[ADDRESS_93002]. Details of 
any relevant medical or surgical history, including allergies , drug sensitivity, and previous ADHD treatments 
will be recorded. All concomitant medicat ions will also be recorded.  
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 32 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL   
7.1.4  Physical examination  
 
An Investigator, or medically qualified designee, will perform the physical examination  at specified time -
points according to  the Study Schedule , which will include assessment of the following body systems: 
central nervous system ( CNS ); eyes; ears, nose and throat (ENT); respi[INVESTIGATOR_696]; cardiovascular; 
gastrointestinal; musculoskeletal; neurological; endocrine/metabolic; hematopoietic /lymphatic;  and 
dermatological.  
 
The outcome of these assessments will be documented in the source document and e CRF and any 
abnormalities will be described.   If any abnormalities are observed, they will be recorded as medical history 
or AEs, pending timing of observatio n.   
 
7.1.[ADDRESS_93003] deemed to be at risk will be excluded from the study.  
 
7.1.7  Body mass index  (BMI)  
 
Height ( cm) and weight (kg) will be measured and recorded in the CRF. BMI will then be calculated a s 
follows:  
 
BMI = (Weight (kg) / (Height  (cm)2) x 10,[ADDRESS_93004] be between 18.0 – 35.0 inclusive to be eligible for study participation.  
 
7.1.8  Vital signs  
 
Arterial blood pressure and heart rate will be recorded  at screening and  at specified time -points according 
to the Study Schedule  when subjects are resting in a sitting position for a minimum of 5 minutes; vital signs 
and time must be recorded in the source document and e CRF.    
 
Data must be collected in the source and eCRFs.  If Blood Pressure window overlaps with PK window, BP 
should be taken prior to PK draw.  
 
Vital signs should be taken at the protocol -specified time (± 10 minutes)  for the tolerability day, 
assessment/ treatment  days, and non -treatment days.  
 
An Investigator can interpret individual findings based on the subject’s age, physical state and level of 
fitness. Subjects with vital signs outside the normal range which, in the investigator’s opi[INVESTIGATOR_1649], are not 
clinically signi ficant  and would not affect the subject’s safety during the study may be included ; this 
decision will be documented in the source document and e CRF. 
 
Protocol CTx-[ADDRESS_93005] blood samples for hematology ,   
biochemistry analysis , and TSH  at screening and check -in (Day -4). Blood samples for serology (HIV, 
HBsAg, and HCV antibody) will be taken at screening only. Urine samples for urinalysis will be collected at 
screening , check -in at Day -4, and EOS /ET.  A wom an will be considered to have no child -bearing potential 
if they are surgically sterile (hysterectomy, tubal ligation, or endometrial ligation) or post-menopaus al ([ADDRESS_93006] menses). For women of child -bearing potential, s erum HCG will be collected/analyzed at 
screening , check -in (Day -4), and EOS/ET .  Values for the laboratory safety tests must be within normal 
ranges (as defined by [CONTACT_85329] ) or considered not clinically significant  (NCS)  by a 
medically qualified designee  for the subject  to be eligible for the study .  The results of all tests conducted 
at Day -[ADDRESS_93007] be available and reviewed before the tolerability day on Day -3.   
 
Blood samples for hematology , biochemistry , TSH,  and urine samples for urinalysis  will be repeated at  the 
EOS visit  and should be reviewed for clinically significant changes from screening; if clinically significant 
changes are observed, they should be recorded as AEs.  
 
The following tests will be carried out:  
 
Hematology  
White Blood Cell (WBC)  and differential, R ed Blood Cell (RBC) , Hemoglobin  (Hb), Hematocrit  (Hct), 
Mean Cell Volume ( MCV ), Mean Cell Hemoglobin  (MCH ) and platelets.  
 
Biochemistry  
Sodium , potassium , chloride , BUN , creatinine , alkaline phosphatase , bilirubin , albumin , adjusted 
calcium, phosphate, aspartate aminotransferase ( AST), alanine aminotransferase ( ALT), gamma -
glutamyl transpeptidase (GGT ), glucose and urate . 
 
Thyroid  
Thyroid Stimulating Hormone (TSH)  
 
Serology  
HIV-1, HIV -2, Hep -B, and Hep -C 
 
Urinalysis  
Bilirubin, urobilinogen, ketones, glucose, proteins, blood, nitrite, pH, specific gravity, and leukocytes.  
 
All subjects with any clinically significant laboratory finding or other significance will not be eligible for the 
study and will be advised to follow up with their own PCP or walk -in clinic.  
 
7.1.[ADDRESS_93008] and serum screen for pregnancy  and drugs of abuse  
 
Urine samples will be tested  at screening and check -in at Day -4 for levels of the following drugs  of abuse : 
amphetamines, methylphenidate, benzodiazepi[INVESTIGATOR_1651], cocaine, methamphetamine and morphine/opi[INVESTIGATOR_858].  
THC will also be assessed for abuse but will be considered exclusionary at the discretion of the investigator.  
A breath alcohol test will also be performed at screening and check -in at Day -4.  
 
Subjects  testing positive for any exclusion ary substances  (other than ADHD prescribed medication)  at 
screening or at check in on Day -[ADDRESS_93009] negative for all ADHD 
medications at check -in on Day -4 to be eligible for the study.  If THC is positi ve at  screening or  check -in, a 
cannabis intoxication evaluation will be done by [CONTACT_85318] -in on Day -4; inclusion will be at 
the investigator’s discretion , due to the slow release of THC from adipose tissue.  
 
Protocol CTx-[ADDRESS_93010] at screening , check in on Day -4, and 
EOS/ET ; HCG must be negative to be eligible for the study.   
 
Repeat  urine analysis may be conducted at the discretion of an Investigator.   Investigator may also opt to 
conduct a urine screen at an unscheduled day to ensure compliance with the protocol.  
 
7.[ADDRESS_93011]’s 
continued eligibility  for the study by [CONTACT_85330], as outlined in Sections  4.[ADDRESS_93012] day in clinic  (EOS ). 
 
 
8 PHARMACOKINETICS  
 
8.1 PHARMACOKINETIC BLOOD SAMPLING  
 
At each Assessment Day blood samples will be drawn by [CONTACT_85331] -points to allow an assessment of methylphenidate  
concentrations in the plasma.  PK draws should be in the same arm throughout the study , if possible . The 
arm used for PK draws should be recorded for each PK timepoint . 
 
The total blood volume taken at each time -point will be approximately 5 mL (4 mL sample  volume  and 1 
mL waste  volume).  There is a risk of bruising and fainting during the blood sampling procedure.   See AE 
section for reporting procedure -related AEs.  
 
A pre -dose  (0) blood sample will be taken no more than 60 minutes prior to dosing.   Blood samples will  
then be withdrawn at specified intervals: 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, [ADDRESS_93013] number, Assessment Day, and time -point  as a minimum .  Blood samples 
should be kept in ice/water bath until centrifugation. Blood samples will be centrifuged at 1,500 g for 10 
minutes at 4°C wit hin  60 minutes of collection.  A minimum of 0.5 mL plasma should be aliquoted into two 
polypropylene  tubes (Primary and Backup); if there is not sufficient plasma  for both,  preference should be 
given to the Primary sample. Each plasma sample should be kept in an ice/water bath environment until 
storage. Each plasma sample must be stored at -20ºC nominal within 30 min of centrifuging .  
 
The actual sample times (times samples actually taken) should be recorded on the Blood Sampling Source 
Document  and should be entered at the time of sampling. Time collected should be reported as the start of 
the sampling collection , defined as the actual drawing of blood volume . The actual times must be recorded 
in the 24-hr format. An y blood sample taken  more than ± 5 min outside of the set sampling times  will be 
recorded as a protocol deviation . 
 
8.2 BIOANALYSIS OF PLASMA SAMPLES  
 
The analysis of these samples will be undertaken by a  Sponsor -approved laboratory. Blood samples for PK 
determination will be processed, split, stored, and shipped according to the sample processing instructions 
supplied by [CONTACT_85332].   Samples will be evaluated using a validated d -MPH method (see 
Bioanalytical Plan for further information on collection, methods, and validation).   
  
Pharmacokinetic metrics to be evaluated are:  AUC 0-inf, AUC last, K, T 1/2, Cmax, tmax, and t lag, including p artial 
AUCs ( AUC 0-3, AUC 3-6, AUC 6-9, AUC 9-12, and AUC 12-16).  Graphical analysis will use protocol -stated times.  
PK analysis will use exact blood draw time , defined above.  
 
Additional parameters may also be calculated if considered appropriate.  
 
 
9 SAFETY MEASUREMENTS AND EVALUATIONS  
 
9.1 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS  
 
An Investigator and site staff are responsible for detecting, documenting, and reporting events that meet 
the definition of an A dverse Event (AE), Serious Adverse Event (SAE)  or Suspected Unexpected Serious 
Adverse Reaction  (S[LOCATION_003]R) . 
 
9.1.[ADDRESS_93014].  
An AE can therefore be any unfavorable and unintended sign (including an abnormal laborat ory finding), 
symptom, or disease (new or exacerbated) temporally associated with the use of an investigational product.  
Events meeting the definition of an AE include, but are not limited to:   
• Exacerbation  (worsening)  of a chronic or intermittent pre -existing condition including either 
an increase in frequency and/or intensity of the condition.  
• New condition(s) detected or diagnosed after investigational product administration even 
though it may have been present prior to the start of the study.  
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 36 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL  • Signs, sy mptoms, or the clinical sequelae of a suspected interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either investigational 
product or a concomitant medication (overdose per se  should not be reported as an 
AE/SAE).  
Events that do not meet the definition of an AE include : 
• Medical or surgical procedure (e.g ., endoscopy, appendectomy); the condition that leads 
to the procedure is an AE.  
• Situations where an untoward medical occurrence did not occur (social and/or convenience 
admission to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day fluctuations of pre -existing disease( s) or condition(s) present or 
detected at the start of the study that do not worsen.  
• The disease/disorder being studied, or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the subject’s 
condition.  
• Pregnancy (of a study  subject or partner of a study  subject), although any medical 
conditions arising from pregnancy may be classed as an AE.  
Clinical AEs should  be described by [CONTACT_85333] (e.g., upper respi[INVESTIGATOR_19629] (URI),  seasonal allergy, etc. instead of runny nose).  
Serious adverse event  
An SAE is any untoward medical occurrence that, at any dose:  
a) Results in death.  
b) Is life -threatening.  
NOTE: The term 'life -threatening' in the definition of 'serious' refers to an event in which the subject was at 
risk of death at  the time of the event.  It does not refer to an event, which hypothetically might have caused 
death, if it were more severe.  
c) Requires hospi[INVESTIGATOR_869] . 
NOTE:  In general, hospi[INVESTIGATOR_85298] (usually involving at least an 
overnight stay) at the hospi[INVESTIGATOR_22771]/or treatment that would not have 
been appropriate in the physician’s office or out -subject  setting.  Complications that occur during  
hospi[INVESTIGATOR_85299].  If a complication prolongs hospi[INVESTIGATOR_85300], the 
event is serious.  When in doubt as to whether “ hospi[INVESTIGATOR_059] ” occurred or was necessary, the AE should 
be considered serious.  
If hospi[INVESTIGATOR_85301] a pre -existing condition which did not worsen from 
baseline , it is not considered an AE.  
d) Results in disability/incapacity, or  
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 37 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL  NOTE:  The term disability means a substantial disruption of a person’s ability to conduct normal life 
functions.  This definition is not intended to include experiences of relatively minor medical significance 
such as uncomplicated headache, nausea, vomiting, diarrhea , influenza, and accidental trauma (e.g., 
sprained ankle) which may in terfere or prevent everyday life functions but do not constitute a substantial 
disruption.  
e) Is a congenital anomaly/birth defect.  
Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other 
situations, such as  important medical events that may not be immediately life -threatening or result in death 
or hospi[INVESTIGATOR_85302].   These should also be considered serious.  
Examples of such events are invasive or malignant cancers, intensive treatment in an emergency room or 
at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059] , or 
development of drug dependency or drug abuse or reports of spontaneous abortion.  
9.1.[ADDRESS_93015] drug has not yet  been administered.  Assessments obtained at Screening 
should be recorded as medical history unless related to study procedure. AEs collected after randomization 
should be evaluated for relatedness to study drug, study procedures, or both. AEs will be asse ssed  until 
the end of the study  (EOS) , early termination (if applicable), or until resolved or stabilized.   
 
SAEs will be collected over the same time period and same process as stated for AEs. SAEs should be 
evaluated by [CONTACT_978] [INVESTIGATOR_85303] . Scientific rationale for attribution to drug 
or procedures should be recorded in the source document and eCRF. SAEs must  be reported to the 
Sponsor within [ADDRESS_93016]’s medical history.   
Medical conditions that are exacerbated while on study should be evaluated as to normal fluctuation  of 
disease state or relation to study drug or pro cedure.  
 
Reporting adverse events  
 
Adverse events can be reported at any time while on study and site should record in the AE source 
document as well as the AE section of the eCRF.  
 
Any new m edical conditions  not present prior to participation in the study  reported by [CONTACT_85334] (described above) should be recorded as stated above . AEs must be recorded 
in detail on both the AE source document and in the eCRF.  If the same AE occurs multiple times, the AE 
is to be recorded  for each occurrence. AEs should also be recorded as reported .   
 
After randomization on Day 0, AEs will be evaluated for relation to study drug or study procedure.   
 
9.1.3  Adverse event grading and assessments  
 
Intensity grading  
 
All AEs will be graded on a three -point scale and reported in detail as indicated on the CRF:  
 
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 38 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL  • Mild – easily tolerated, causing minimal discomfort and not interfering with normal everyday 
activities  
 
• Moderate – sufficiently discomforting to interfere with normal everyday activities  
 
• Severe – incapacitating and/or prevents normal everyday activities  
 
Relationship assessment  
 
Study drug or study procedure  relationship for each AE should be determined by [CONTACT_85335]:  
 
• Not related to Study Drug  
o The AE does not follow a reasonable temporal sequence from investigational product 
administration or can be reasonably explained by [CONTACT_423]’s clinical state or other 
factors (e.g., disease under study, concurre nt diseases, and concomitant medications).  
 
• Related  to Study Drug  
o The AE follows a reasonable temporal sequence from the investigational product 
administration and cannot be reasonably explained by [CONTACT_423]’s clinical state or other 
factors (eg, disease under study, concurrent diseases, or concomitant medications).  
o The AE follows a reasonable temporal sequence from the investigational product 
administration and represents a known reaction to the investigational product under study or 
other drugs in its class or is predicted by [CONTACT_85336] t he drug.   
o The AE resolves with discontinuation of the investigational product and/or recurs with 
rechallenge, if applicable.  
 
• Procedure  related   
o The event is not related to the study drug but is related to the subject’s participation in the study 
in another capacity, for example: bruising d ue to venipuncture or intolerability of Focalin XR [ADDRESS_93017] to follow -up.  
 
In addit ion, any SAEs will be followed up to resolution (or the other criteria as outlined above).  If any serious 
related event is not resolved (or does not meet any other criteria outlined above) prior to the completion of 
the final report, the report will be is sued. If additional information becomes available following the 
completion of the report an addendum will be generated detailing the follow up information. Any follow -up 
information on SAEs must be reported to the Sponsor within [ADDRESS_93018] learning of the SAE to CRO  via the following  
SAE fax/e -mail address.  Additionally, the SAE should be recorded into the EDC.  
 
Table 8 
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 39 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL   
Premier Research Pharmacovigilance  
Email  GlobalPV -US@premier -research.com   
Fax number  [PHONE_2003] -972-8765  
 
 
It is essential to enter the following information:  
• Protocol and subject identifiers  
• Subject’s demography  
• Description of events, with diagnosis if available  
• Investigator opi[INVESTIGATOR_85304]  
• Criterion for seriousness  
 
The following are desirable and are of particular relevance for assessment of the adverse event report:  
 
• Date of onset of SAE  
• Date SAE stopped, if relevant  
• Study treatment start date  
• Study treatment end date if relevant  
• Action taken on study treatment  
• Outcome if known  
 
The initial report will be followed up with more information as relevant.  This may require an Investigator to 
obtain copi[INVESTIGATOR_3103], autopsy reports and other documents as applicable.   If CRO or 
Sponsor request copi[INVESTIGATOR_85305] -identifying information such as hospi[INVESTIGATOR_85306], the forms should be 
redacted,  and the subject number should be written on the forms for study identification.   
 
Reporting of S[LOCATION_003]Rs  
 
Where the adverse reacti on is unexpected and serious it may be termed Suspected Unexpected Serious 
Adverse Reaction  (S[LOCATION_003]R). Study site personnel should ensure all relevant information is provided to the 
Sponsor to allow the Sponsor to meet their obligations to report any S[LOCATION_003]R t o the relevant competent 
authority.  
 
S[LOCATION_003]Rs will be reported, by [CONTACT_779], to Sponsor or CRO within [ADDRESS_93019] becoming aware of 
the event. The Sponsor or designee will then carry out reporting as follows:  
 
S[LOCATION_003]Rs which are fatal or life -threatening : reporting to the Ethics Committee and FDA  within 7 days 
of becoming aware of the event. A more detailed report will be provided within an additional 8 days.  
 
All other S[LOCATION_003]Rs : reporting to the Ethics Committee  and FDA  within [ADDRESS_93020] at screening , check -in at Day -4, and 
EOS/ET. All subjects  of child -bearing potential must use a double -barrier method  form of birth control  or 
meet other birth control methods  as defined per protoc ol, while on study.  Females that are confirmed 
pregnant during screening and/or before randomization  are excluded from the study.  Females that are 
breastfeeding during screening and/or before randomization, and/or for [ADDRESS_93021] pregnancy information on the appropriate  pregnancy data 
collection  form and submit it to the CRO within 2 4 hours  of learning of the pregnancy.  
 
While pregnancy itself is not considered to be an AE, any pregnancy complication or elective termination 
for medical reasons will be recorded as an AE or SAE as defined in Section  9.1.2 . Note that termination 
itself is not an AE, only any medical reasons for a termination should be recorded as an AE.  
 
A spontaneous abortion is always considered to be an SAE and will be reported as such. An SAE occurring 
in association with a pregnancy, brought to the Investigator’s attention  after the subject completed the study 
and considered by [CONTACT_85337], must be promptly 
recorded.  
 
The Investigator, or designees, should report pregnancy only, or pregnancy with an associated SAE, 
immediately to the CRO  via the following  fax/e -mail address.   
 
Premier Research Pharmacovigilance  
Email  GlobalPV -US@premier -research.com   
Fax number  [PHONE_2003] -972-8765  
 
 
9.3 LABORATORY EVALUATIONS RELATED TO SAFETY  
 
Clinical safety laboratory assessments ( hematology , biochemistry and urinalysis) will be conducted during 
the screening day and at check -in (Day -4) to ensure the subject’s good  health.   Subjects with clinically 
significant labs at screening  and/or at check -in (Day -4), as assessed by [CONTACT_39595] , should not be 
enrolled in the study.  Clinical  safety laboratory assessments will be repeated  at EOS (or ET day, if 
applicable)  to ensure the subject’s health has not been adversely affected by [CONTACT_85338] r participation in this study. 
Abnormal  results  detected at EOS (or ET day, if applicable)  which differ from check -in labs (Day -4) and 
the Investigator considers to be clinically significant, will be recorded as an AE . 
 
Clinically significant findings in laboratory tests at screening and/or at  check -in on Day -4, will be considered 
pre-existing conditions  (medical history) , as well as failure to meet eligibility criteria; they will not be 
considered AEs. However,  for any medical event or condition discovered at screening , which, in the opi[INVESTIGATOR_85307] , is significant enough to be followed up externally , subject will be asked to follow up with 
their primary care physician . 
 
9.[ADDRESS_93022] is, and remains in, good general health. Abnormal 
findings that the Investigator considers to be clinically significant, other than at screening, will be recorded 
as an AE.  
 
 
10 STATISTICAL/ DATA ANALYSIS METHODS  
 
10.1 GENERAL CONSIDERATIONS  
This section describes the rules and conventions to be used in the presentation  and analysis of the data. 
A comprehensive presentation of the data management  plan and statistical analysis  plan will be approved 
by [CONTACT_85339].  
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 41 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL   
10.2 STATISTICAL AND ANALYTICAL PLAN  
This is a randomized, single -dose, four -sequence,  four-period, in -clinic  crossover PK study to evaluate 
PK concentrations of d -MPH in the investigational drug compared to the registered  listed drug (RLD)  
under fasted conditions .   
 
The following variables will be assessed  over the course of the study, by [CONTACT_85340] : AUC 0-inf, AUC last, 
and C max, including  partial AUCs ( AUC 0-3, AUC 3-6, AUC 6-9, AUC 9-12, and AUC 12-16).  Additional parameters 
may also be evaluated.  
 
Safety will be assessed by [CONTACT_85341], concomitant medications, physical exams, vital signs, and 
ECGs. 
 
10.[ADDRESS_93023] (Focalin XR) to CTx -
[ADDRESS_93024] are the key PK endpoints which will be used to evaluate the relative 
bioavailability of CTx-1301 6.25 mg vs. Focalin TM XR 5 mg ( treatment B vs. treatment A) and CTx-1301 
50 mg vs. Focalin TM XR 40 mg  (treatment D vs. treatment C). The basis of evaluation for these endpoints 
will be 90% confidence intervals for the ratio s of adjusted geometric means as described in Section 10.7. 
In the context of a bioavailability analysis, similarity will be concluded if the 90% confidence interval (CI) 
of the geometric mean ratios for Cmax, AUCinf, AUClast fall ne ar or within the 90% CI of [0.80 —1.25]. 
This is the same as performing two one -sided hypothesis tests (TOST procedure), each conducted at a 
5% siginicant level. The TOST procedure will identify two treatment s as equivalent when the lower bound 
of a 90% con fidence interval falls near or below 1.25 or the upper bound of a confidence interval falls 
near or above 0.80 (or both).   
 
Based on the conservative TOST methodology  assumptions, that the bioavailability analysis falls within 
the 90% CI of [0.80 —1.25] , a sample size of at least [ADDRESS_93025] 8 8% power with 
the assumption of within -subject CV (coefficient of variation) of 17 -21% and true bioavailability ratio ( B/A 
and D/C ) of 93 -107%.  With assumption of the drop -out rate of 1 1%, 36 subjects total ( 6-12 subjects per 
cohort ) will be randomized. No adjustment for multiple comparisons will be made.  
 
 
10.5 ANALYSIS POPULATIONS  
 
• Safety Population (SAF ): The SAF Population includes all subjects who receive at least 1 dose 
of study drug.  
• PK Population : The PK Population includes all subjects who receive at least [ADDRESS_93026] one evaluable PK plasma concentration . 
 
 
10.6 DEMOGRAPHIC AND BASELINE CHARACTERISTICS  
 
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 42 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL  Baseline data, relevant screening data and demographic characteristics will be summarized  for the safety 
population . 
 
 
10.7 PHARMACOKINETIC ANALYSIS  
 
Pharmacokinetic sample analysis will be performed by a central  laboratory . The results will be shared with 
the CRO for the PK parameter calculations and the final PK  analysis report.  
 
Pharmacokinetic analysis  will be based on PK population. Plasma CTx-1301  and Focalin TM XR 
concentrations will be summarized descriptively by [CONTACT_85342].  
 
Pharmacokinetic parameters  (including AUC 0-inf, AUC last, K, T 1/2, Cmax, tmax, and t lag) will be summarized 
descriptively by [CONTACT_85343].   Partial AUCs and dose-normalized PK parameters 
(including dose normalized AUC 0-, AUC last, Cmax) will also be calculated (by [CONTACT_85344]) and 
summarized similarly.  
 
Natural log -transformed pharmacokinetic parameters (including AUC 0-inf, AUC last, and C max) will be analyzed 
using a mixed -effect model with sequence, period, and treatment as fixed effects and subject within 
sequence as a  random effect .  A sensitivity analysis may be conducted  to analyze any unexpected 
differences among cohort s.  Estimates of the adjusted mean differences ( CTx-1301 6.25 mg vs. Focalin TM 
XR 5 mg and CTx-1301 50 mg vs. Focalin TM XR 40 mg ) and corresponding 90% confidence intervals will 
be obtained from the model.   The adjusted mean differences and 90% confidence intervals for the 
differences will be exponentiated to provide estimates of the ratio of adjusted geometric means (Treatment 
B/A and Treatment D/C) and 90%  confidence intervals for the ratios.  
 
Natural log -transformed , dose -normalized , pharmacokinetic parameters (including AUC 0-inf, AUC last, and 
Cmax) will also be analyzed using a mixed -effect model with sequence, period, and treatment as fixed effects 
and subject within sequence as a random effect .  A sensitivity analysis may be conducte d to analyze any 
unexpected differences among cohorts.  Estimates of the adjusted mean differences ( CTx-1301 6.25 mg 
vs. Focalin TM XR 5 mg and CTx-1301 50 mg vs. Focalin TM XR 40 mg ) and corresponding 90% confidence 
intervals will be obtained from the model.   The adjusted mean differences and 90% confidence intervals for 
the differences will be exponentiated to provide estimates of the ratio of adjusted geometric means 
(Treatment B/A and Treatment D/C) and 90%  confidence intervals for the ratios.  Dose p roportionality will 
also be evaluated based on the model for dose -normalized parameters, using a ratio of adjusted gometric 
means (Treatment C/B) for comparison of the CTx -1301 50 mg and CTx -1301 6.25 mg groups, along with 
corresponding 90% confidence inte rvals.  
 
Natural log -transformed , dose -normalized , pharmacokinetic parameters (including AUC 0-inf, AUC last, and 
Cmax) will also be analyzed to evaluate dose proportionality of CTx-1301 using the 6.25 mg and 50 mg 
doses.    
 
Exploratory analyses may be conducted  to examine potential differences between treatments (CTx-1301 
6.25 mg vs. Focalin TM XR 5 mg and CTx-1301 50 mg vs. Focalin TM XR 40 mg )  within selected time intervals.   
 
Additional details of pharmacokinetic analysis will be included in the statistical analysis plan.  
 
PK plasma concentrations of d-MPH  will be summarized  by [CONTACT_12268].  
 
10.8 SAFETY  ANALYSIS  
 
Safety analysis will be performed for the Safety Population.  
 
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 43 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL  Safety will be assessed by [CONTACT_85345] -emergent adverse 
events (TEAEs), labo ratory tests , ECGs, physical exams, C -SSRS,  and vital  signs . No inferential testing 
for statistical significance will be performed.  
 
Adverse events will be classified using Medical Dictionary for Regulatory Activities (MedDRA) classification 
system.  Adverse events will be summarized by [CONTACT_85346] , preferred term, severity , and relationship to treatment.  
 
Data for laboratory tests , vital signs , ECG, physical exams and C-SSRS  will be summarized descriptively.   
More details will be provided in the statistical analysis plan (SAP).  
 
11 ETHICAL AND REGULATORY ASPECTS  
 
11.1 LOCAL REGULATIONS/DECLARATION OF HELSINKI  
 
The Principal Investigator [INVESTIGATOR_85308], as well as the Declaration of Helsinki , ICH, 
GCP,  and GLP  Guidelines . 
 
11.2 INFORMED CONSENT  
 
It is the responsibility of the Investigator, or medically qualified designee, to obtain written (signed and dated 
by [CONTACT_423]) informed consent from each individual participating in this study. Major/substantial 
amendments to the protocol that affect t he scope of the study at the subject level and/or updates to the 
safety profile of an investigational product will be reflected in the updated consent form and active subjects 
will be re -consented.   Refer to Section 7.1.1 . 
 
 
11.3 INDEPEND ENT ETHICS COMMITTEE /INSTITUTIONAL REVIEW BOARD  
 
This protocol (and any modifications) as well as appropriate consent procedures, will be reviewed and 
approved by [CONTACT_18369] /IRB.  This body must operate in accordance with the current local requirements. A 
letter or certificate of approval must be received prior to initiation of the study, and also when subsequent, 
substantial modifications to the protocol are made.  
 
If the study is stopped due to adverse events, it will not be recommenced wi thout reference to the IEC /IRB 
responsible for the study.  
 
The outcome of the study (e.g. completed) will be reported to the IEC /IRB responsible for the study within 
[ADDRESS_93027]’s final study procedures. In the event of the study being 
prematurely terminated, a report will be submitted to the IEC /IRB responsible for the study within [ADDRESS_93028] 
KEEPI[INVESTIGATOR_1645]  
 
12.1 INVESTIGATOR ’S FILES/RETENTION OF DOCUMENTS  
 
The Investigator will maintain adequate and accurate records to enable the conduct of the study to be 
fully documented and the study data to be subsequently verified. These documents will be classified into 
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 44 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL  two categories: (1) Study  Regulatory  file, and (2 ) study/subject clinical source documents (including CRF). 
The site ’s regulatory  file must be held at the study site for as long as needed to comply with national and 
international regulations.  The Sponsor will notify the investigator(s)/institution(s) wh en the study -related 
records are no longer required.  The investigator agrees to adhere to the document retention procedures 
by [CONTACT_12142].  Essential documents include:  
• IRB/IEC  approvals for the study protocol and all amendments  
• All source docum ents and laboratory records  
• CRF copi[INVESTIGATOR_014] (electronic copi[INVESTIGATOR_85309] a CDROM  or USB/thumb drive ) 
• Subject s' informed consent forms (with study number and title of study ) 
• FDA form 1572  
• Any other pertinent study document.  
 
12.2 SOURCE DOCUMENTS/DATA  
 
The source documents (e.g. , clinical and office charts, laboratory notes, memoranda, subjects’ diaries or 
evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_35418], sub ject files and records kept at the 
pharmacy, at the laboratory and at the medico -technical departments involved in the clinical study) which 
contain the source of data recorded in the eCRF,  and source data recorded directly into the eCRF (e.g. , 
inclusion/e xclusion criteria , subject enrol lment)  should be specified in a source document designation form.   
 
12.[ADDRESS_93029] is withdrawn from the study because of a 
treatment -limiting AE, thorough efforts should be clearly made to document the outcome  and provide the 
reason for withdrawal from the study as an AE  in the eCRF . 
 
All source documents  should be complet ed during (or immediately after) a subject assessment. Source 
documents should be completed in a GCP -compliant manner. The text should be written with a  black  or 
blue ballpoint pen and must be legible. If a source document  entry needs correction, the error  should be 
crossed out with a single line (not obliterated or covered with correction fluid) and the correct information 
should be written next to the original entry. The change must be initialed  and dated by [CONTACT_47362].  
 
The study monito r(s) will review all source documents and e CRFs and any queries will be highlighted to 
the Investigator, or designee(s), enabling the errors to be addressed prior to data lock of the eCRF pages.  
 
12.[ADDRESS_93030] for status and ranking  of con tributors.  Contrib utions  of the participating investigators, 
institutions, CRO, and Sponsor  will be listed, unless otherwise requested.  
 
13 PROCESS FOR AMENDING THE PROTOCOL  
 
All major/substantial protocol modifications must be reviewed and approved by [CONTACT_85347] /IRB.  
Approval from the IEC/ IRB must be received  before the revised edition can be implemented.  
 
Protocol CTx-[ADDRESS_93031] to subjects do not require pre -approval by [CONTACT_12137]/IRB, but the IEC /IRB will be notified  of these amendments.  
 
 
14 CONDITIONS FOR TERMINATING THE STUDY  
 
It is agreed that for reasonable cause, the Sponsor may terminate this study, provided a written notice is 
submitted at a reasonable time in advance of intended termination  and  provided to each investigator.  If 
the study is terminated prematurely or suspended, the IE C/IRB  will be informed and provided with the 
reason(s) for termination or suspension by [CONTACT_12942]/institution, as specified by 
[CONTACT_76542] e regulatory requirement.  
If a drug -related S[LOCATION_003]R  occurs at any time during the study, the Medical Monitor and Sponsor  will review 
the case immediately.  
The study will not be restarted until all parties have agreed to the course of action to be taken and t he 
IRB/EC has been notified.  
If terminating the study, the S ponsor will assure that adequate consideration is given to the protection of 
the Subject’s interests.  
 
 
[ADDRESS_93032] ensure that subjects’ anonymity is maintained.  Subjects should not be identified by 
[CONTACT_85348] , but by a subject identification code  (screening number or subject 
enrollment/randomization number).  
 
The Investigat or should keep a separate log of subjects’ codes and names. Documents which may identify 
the subject, e.g. , subjects’ written consent forms, hospi[INVESTIGATOR_1097], etc. will be maintained in strict 
confidence. Any electronic files that contain subjects’ persona l data will be appropriately encrypted.  
 
 
16 AUDITS/INSPECTIONS  
 
The Investigator and study subjects should understand that source documents for this study should be 
made available to appropriately qualified personnel or designee(s) from health authority insp ectors after 
appropriate notification. The verification of the eCRF data may be by [CONTACT_85349] 
(where permitted by [CONTACT_2371]) or through an interview exchange . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol CTx-1301 -001                               Version 4.0 16 January 2020                    Page 46 of 47 
Cingulate Therapeutics                                                                         CONFIDENTIAL   
 
 
 
 
 
 
17 REFERENCES  
 
1. Cantwell DP. 1996. Attention deficit disorder: A review of the past 10 years. J Am Acad Child Adolesc 
Psychiatry, 35:978 -987. 
2. Dulcan M. 1997. Work group on quality issues. Practice parameters for the assessment and treatment 
of children, adolescents, and adults with attention -deficit/ hyperactivity disorder. J Am Acad Child 
Adolesc Psychiatry, 36:85S -121S.  
3. Swanson JM, Seargent JA, Taylor E, et al. 1998. Attention deficit disorder and hyperkinetic disorder. 
Lancet, 351:429 -433. 
4. Kessler, R.C. (201 6, February 04). How ADHD Grew Up as Kids Grew into ADHD Adults. Retrieved 
from https://apsard.org/how -adhd -grew -up-as-kids-grew -into-adhd -adults/  . 
5. Mannuzza S, Klein RG, Bessler A, et al. 1998. Adult psychiatric st atus of hyperactive boys grown up. 
Am J Psychiatry, 155:493 -498. 
6. Bradley C. 1937. The behavior of children receiving benzedrine. Am J Psychiatry, 94:577 -585. 
7. Greenhill LL, Pliszka S, Dulcan MK, et al. 2002. American Academy of Child and Adolescent 
Psychiat ry. Practice parameter for use of stimulant medications in the treatment of children, 
adolescents, and adults. J Am Acad Child Adolesc Psychiatry, 41([ADDRESS_93033]):26S -49S. 
8. Kimko HC, Cross JT, Abernethy DR, et al. 1999. Pharmacokinetics and clinical effectivene ss of 
methylphenidate. Clin Pharmacokinet, 37(6):[ADDRESS_93034] JW , Quinn D , et al.  1992 Enantioselective pharmacokinetics and 
pharmacodynamics of dl -threo -methylphenidate in children with attention deficit hypera ctivity disorder. 
Clin Pharmacol Ther.  52(5):561 -8. 
10. Quinn D, Wigal S, Swanson J, et al. 2004. Comparative pharmacodynamics and plasma 
concentrations of  d-threo -methylphenidate hydrochloride after single doses of d -threo -
methylphenidate hydrochloride and d,l -threo -methylphenidate hydrochloride in a double -blind, 
placebo -controlled, crossover laboratory school study in children with attention -deficit/hyper activity 
disorder. J Am Acad Child Adolesc Psychiatry, 43(11):1422 -9. 
11. Patrick KS, Caldwell RW, Ferris RM, et al. 1987. Pharmacology of the enantiomers of threo -
methylphenidate. J Pharmacol Exp Ther, B: [ADDRESS_93035] JW, Midha KK. 1986. Development of enantioselective gas chromatographic 
quantitation assay for d.l -threo -methylphenidate in biological fluids. J Chromatography, A 378(1):[ADDRESS_93036] JW, et al. 1987. Stereoselective disposition of methylphenidate in 
children with attention -deficit disorder. J Pharmacol Exp Ther, 241(1):[ADDRESS_93037] Hanover, New Jersey, 2005  
15. Silva R, Tilker HA, Cecil JT, et al. 2004. Open -label study of dexmethylphenidate  hydrochloride in 
children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc 
Psychopharmacol, 14(4):[ADDRESS_93038] Hanover, New Jersey, 
May 2005  
17. Brams, M.,  Muniz, R.,  Childress, A.  Giblin, J.,  Mao, A., Turnbow, J,  Borrello, M.,    McCague, K., Lopez, 
F., Silva, R. 2008. A randomized, double -blind, crossover study of once daily dexmethylphenidate: 
Rapid onset of effect. CNS Drugs 22(8):693 -704.  
18. Silva, R, Muniz, R, McCague, K, Childress, A, Brams, M, Mao, A 2008 : Treatment of Children With 
Attention -Deficit/Hyperactivity Disorder (ADHD): Results of a Randomized, Multicenter, Double -Blind, 
Crossover Study of Extended -Release Dexmethylphenidate and d,l-Methyl phenidate and Placebo in 
a Laboratory Classroom Setting. Psychopharmacology Bulletin 41(1)19 -33. 
19. [COMPANY_001]. Focalin (dexmethylphenidate hydrochloride) tablets prescribing information. East Hanover, 
NJ; 2015, Apr  
 
20. [COMPANY_001]. Focalin XR (dexmethylphenidate hyd rochloride) extended -release capsules prescribing 
information. East Hanover, NJ; 2015 – Jun 
 
21. Aurora SK, Kori AH, Barrodale P, et al. (2006) Gastric stasis in migraine: More than just a paroxysmal 
abnormality during a migraine attack. Headache. 46:57 -63. 
22. Horowitz MHP, Maddox A, Maddern GJ et al. (1986) Gastric and oesophageal emptying in insulin 
dependent diabetes mellitus. J Gastroenterol Hepatol . 1: 97 -113. 
23. Prescott LF, Yoovathaworn K, Makarananda K et al. (1993) Impaired absorption of paracetamol in 
vegeta rians. Br. J. Clin. Pharmacol. 36:237-240. 
24. Wald A, Thiel DHV, Hoechstetter L et al. (1981) Gastrointestinal transit: the effect of the menstrual 
cycle. Gastroenterology 80:1497 -1500.  
25. Hart D and Wall BF. (2002) Radiation exposure of the [LOCATION_006] population from medical and dental x -ray 
examinations. Oxon, [LOCATION_006]: National Radiological Protection Board.  